Phase II clinical trial of Iguratimod in treatment of rheumatoid arthritis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10000849

Enrollment

Unknown

Registered

2010-04-22

Start date

2005-08-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Tota:Double-blind double-dummy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: RA patients (To be aged 18 year to 65 year) who met revised American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent

Exclusion criteria

Exclusion criteria: disfunction of liver, severe cardiovascular, urinary, hematopoietic and endocrine system diseases, immunodeficiency, uncontrolled infection or active gastrointestinal tract diseases, vaccinated recently, gravida, women in lactation period or intending to become pregnant recently, hypersensitivity to CII, treatment with all other disease modifying anti-rheumatic drugs (DMARDs) within 30 days before enrolment

Design outcomes

Primary

Measure	Time frame
pain, morning stiffness, tender joint count, swollen joint count, health assessment questionnaire;	—

Countries

China

Contacts

Public ContactWei Wei

wwei@ahmu.edu.cn+86 0551 5161208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026